GB04/4775

INVESTOR IN PEOPLE

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales   REC'D **1 4 DEC 2004**
NP10 8QQ

WIPO   PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated   24 November 2004

Form 1/77

nts Act 1977
e 16)

The
Patent
Office

11NOV03 E951039-1' 000019
P01/7700 0.00-0326192.2

equest for grant of a patent

*the notes on the back of this form. You can also
n explanatory leaflet from the Patent Office to
you fill in this form)*

. Your reference	P035883GB

THE PATENT OFFICE
10 NOV 2003
RECEIVED BY HAND

. Patent application number
(The Patent Office will fill in this part)

10 NOV 2003

0326192.2

. Full name, address and postcode of the or of each applicant *(underline all surnames)*	University of Kent The Registry University of Kent Canterbury Kent CT2 7NZ	
Patents ADP number *(if you know it)*		5648 837 006
If the applicant is a corporate body, give the country/state of its incorporation	United Kingdom	
!. Title of the invention	PROTEINS INVOLVED IN SIGNAL TRANSDUCTION	
5. Name of your agent *(if you have one)*	Carpmaels & Ransford	
"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*	43-45 Bloomsbury Square London WC1A 2RA	
Patents ADP number *(if you know it)*	83001	

	Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number			

	Number of earlier application	Date of filing *(day / month / year)*
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application		

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:* *a) any applicant named in part 3 is not an inventor, or* *b) there is an inventor who is not named as an applicant, or* *c) any named applicant is a corporate body* *See note (d))*	Yes

9. Enter the number of sheets for any of the
   following items you are filing with this form.
   Do not count copies of the same document

   Continuation sheets of this form

   Description   24

   Claim(s)   4

   Abstract   1

   Drawing(s)   9 + 9 PH

10. If you are also filing any of the following,
    state how many against each item.

    Priority documents

    Translations of priority documents

    Statement of inventorship and right
    to grant of a patent *(Patents Form 7/77)*

    Request for preliminary examination
    and search *(Patents Form 9/77)*

    Request for substantive examination
    (Patents Form 10/77)

    Any other documents
    (please specify)

11.   I/We request the grant of a patent on the basis of this application.

    Signature   Date

    Campion o Runfe   10th November 2003

    Carpmaels & Ransford

12. Name and daytime telephone number of   Paul N. Howard   020-7242 8692
    person to contact in the United Kingdom

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes
a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
b) *Write your answers in capital letters using black ink or you may type them.*
c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
e) *Once you have filled in the form you must remember to sign and date it.*
f) *For details of the fee and ways to pay please contact the Patent Office.*

Proteins involved in signal transduction

All documents cited herein are incorporated by reference in their entirety.

TECHNICAL FIELD

This invention is in the field of signal transduction in bacteria. More particularly, the invention
5   relates to the mechanism of quorum sensing in bacteria and control of this mechanism by
antibodies and vaccines.

BACKGROUND ART

Quorum sensing is a phenomenon that was first termed in 1994 by Fuqua *et al.* (J. Bacteriology,
176:269-276). However, the phenomenon of "autoinduction" in the bioluminescent organism
10   *Photobacteria fischeri* (later to become *Vibrio fischeri*) which underpinned the development of
quorum sensing research was first described in 1970 by Nealson, Platt and Hastings (J. Bacteriol.
104(1):313-22). Whilst working on the physiology of luminescence of *Photobacteria fischeri*
(*Vibrio fischeri*), they noticed that there was no appreciable amount of luminescence emitted by
the bacteria until the population of cells had reached a concentrated culture. This phenomenon
15   was also noticed in conjunction with the squid *Euprymna scolopes*, where the bacteria colonise
the squid's light organ to a concentration of 10^{10} to 10^{11} cells/ml, causing the organ to glow.
However, when present in diffuse amounts in seawater, no bioluminescence is noticed. It
therefore seemed that the population of bacteria could sense its own concentration and either
initiate the bioluminescent pathway or remain unlit. This mechanism which combines cell-cell
20   communication and cell density is defined as quorum sensing.

In *V. fischeri* the system is controlled by the lux operon which consists of a number of genes
including *luxI*, encoding the autoinducer synthase, and *luxR* which encodes an autoinducer-
dependent activator of the luminescence genes (Sitnikov *et al.* 1995, Mol. Microbiol.17:801-
812). The autoinducer signal molecule, which in many Gram negative bacteria is an N-acylated
25   homoserine lactone (AHL), is excreted by each cell into the surrounding media. This autoinducer
is then taken up by other cells and binds the LuxR receptor protein which then activates the lux
operon, causing the production of luciferase and therefore bioluminescence. Kolibachuk and
Greenberg (J. Bacteriol. 1993, 175(22):7307-7312) proposed a model for the signal transduction
pathway that is used in this process. Their experiments suggested that LuxR is found on the inner
30   surface of the bacterial cytoplasmic membrane. Further evidence of this is given in

"Transcriptional Activation by LuxR" (Stevens and Greenberg, 1999, in "Cell-cell signalling in bacteria" Eds. Dunny & Winams).

The phenomenon of quorum sensing is not just limited to *V. fischeri*, but has been described in a number of Gram-negative and Gram-positive bacteria. Many of these bacteria use quorum sensing to control the production of virulence determinants thus allowing the pathogenic bacteria to avoid host defences until a sufficient population has been reached. Examples of pathogens that utilise quorum sensing include *Bacillus subtilis*, *Streptococcus pneumoniae*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Burkholderia cepacia*, *Yersinia pestis*, *Yersinia enterocolitica* and *Yersinia pseudotuberculosis* (Cámara *et al.* 2002 The Lancet Infectious Diseases 2:667-676). *Pseudomonas fluorescens* is thought to play an important role in Crohn's disease and it is further believed that its quorum sensing signalling molecule plays a role in immune modulation. With the emergence of organisms that are resistant to many antibiotics such as methicillin-resistant *Staphylococcus aureus* (MRSA), quorum sensing represents a novel therapeutic target offering the opportunity to attenuate virulence, thus controlling infection by blocking cell-cell communication.

Biofilms form when bacteria adhere to surfaces in aqueous environments and begin to excrete a slimy, glue-like substance that can anchor them to all kinds of material – such as metals, plastics, soil particles, medical implant materials, and tissue. The production of this "slimy, glue-like substance" and other virulence determinants are thought to be controlled by quorum sensing (Latifi *et al.* 1995, Mol. Microbiol. 17:333-344). A biofilm can be formed by a single bacterial species, but more often biofilms consist of many species of bacteria, as well as fungi, algae, protozoa, debris and corrosion products. Essentially, biofilms may form on any surface exposed to bacteria and some amount of water (Costerton *et al.* 1987, Ann. Rev. Microbiol. 41:435-464). Once anchored to a surface, biofilm microorganisms carry out a variety of detrimental or beneficial reactions (by human standards), depending on the surrounding environmental conditions. Microbial biofilms on surfaces cause billions of dollars yearly of equipment damage, product contamination, energy losses and medical infections.

DISCLOSURE OF THE INVENTION

The present invention is based on the discovery that the protein complexes involved in quorum sensing are found on the outer surface of the bacterial membrane during certain stages of growth. In particular, it has been found that the protein LuxR is an integral part of a signal transduction complex that is found on the outer surface of the *V. fischeri* bacterial membrane. The interaction

of the protein LuxR and homologues thereof with the signal molecule (which for *V. fischeri* is an N-acylated homoserine lactone, specifically N-3-(oxohexanoyl)homoserine lactone) is therefore a target for modulation to control quorum sensing, attenuate virulence and control bacterial growth and /or infection. The finding that the protein LuxR forms part of a signal transduction complex on the outer surface of the bacterial membrane facilitates extracellular modulation of the activation of LuxR or homologue of LuxR. It therefore facilitates modulation of the activation of LuxR or a homologue of LuxR by a ligand, such as an antibody, which is unable to cross the bacterial cell membrane. Furthermore, other bacteria that use quorum sensing have similar signal transduction complexes comprising a homologue of LuxR. One such homologue is the LasR protein of *P. aeruginosa*.

In a first aspect, the invention provides a method of regulating quorum sensing in bacteria comprising modulating the activation by a signalling molecule of LuxR or a homologue thereof. Preferably the modulation is extracellular.

The present invention may be employed in the regulation of any bacteria employing quorum sensing. Proliferation of such bacteria involve distinct stages, namely, pre-quorate, quorate and post-quorate. For modulation, preferably the bacteria are in the pre-quorate or quorate stage, more preferably they are in the pre-quorate stage.

The activation of LuxR or a homologue of LuxR may be upregulated or downregulated. Preferably the activation of LuxR or a homologue of LuxR is downregulated and more preferably is prevented.

Homologues of LuxR are proteins that share a common evolutionary ancestor with LuxR (as described by Gray, K.M. & Garey, J.R., 2001, Microbiology, 147:2379-2387) and are induced in quorum sensing. Homologues of LuxR are described in PROSITE as being members of the LuxR family of proteins (see http://us.expasy.org/cgi-bin/nicedoc.pl?PS00622). Preferably they are proteins that are found on the outer surface of bacterial membranes during the pre-quorate and quorate phases of bacterial growth and which bind a signalling molecule and are then able to activate transcription. Preferably, they are proteins that share sequence identity with LuxR. Preferably homologues of LuxR have residues corresponding to those of LuxR. Preferably homologues of LuxR have residues corresponding to the following residues of LuxR when aligned using the Clustal alignment algorithm (Higgins, D.G., Bleasby, A.J. and Fuchs, R., 1992, CLUSTAL V: improved software for multiple sequence alignment. Computer Applications in the Biosciences (CABIOS), 8(2):189-191): TRP66, TYR70, ASP79, PRO80, GLY121, GLU187

and GLY197. Preferably the homologue of LuxR is selected from the group consisting of AhlR, AhyR, AsaR, BisR, BviR, CarR, CepR, CerR, CinR, CsaR, CviR, EagR, EcbR, EchR, EsaR, ExpR, HalR, LasR, LuxS, Mll8752, MupR, PhzR, PpuR, PsmR, PsyR, RaiR, RhiR, RhlR, SdiA, SdiR, SmaR, SolR, SpnR, SprR, SwrR, TraR, TriR, TrlR, TrnR, VanR, VsmR, Y4qH, YenR, YpeR, YpsR, YruR, YtbR and YukR.

LuxR and the homologues of LuxR use an N-acylated homoserine lactone as the signalling molecule.

Preferably the activation of LuxR or a homologue of LuxR is modulated by providing a ligand capable of binding to LuxR or a homologue of LuxR and thereby blocking activation by the signalling molecule. Preferably, the ligand is an antibody. Most preferably, said antibody is a monoclonal antibody.

By "activation of LuxR or a homologue of LuxR", we mean that LuxR or a homologue is bound by a signalling molecule and is therefore able to activate transcription.

The ligand of the present invention preferably immunoreacts with LuxR or a homologue of LuxR between the negative regulation domain and the autoinducer-binding domain. In the case of LuxR, which is a polypeptide of 250 amino acids, the ligand preferably binds between amino acid residues 19 and 80, more preferably between amino acid residues 19 and 31. More preferably, the ligand employed in the invention immunoreacts with the amino acid sequence TCNNNKDINQC.

The specific sequence which was used for the production of ligands was derived from *V. fischeri* strain ES114.

The method of the invention also includes the use of antibodies that immunoreact with those ligands which immunoreact with LuxR or a homologue of LuxR. These anti-idiotypic antibodies may then be used to sequester the signalling molecules that activate LuxR or homologues of LuxR. Preferably the anti-idiotypic antibodies of the invention immunoreact with N-acylated homoserine lactones.

Ligands used in the invention may be conjugated to a detectable label. Preferred labels include radioisotopes, fluorescent labels, heavy metal molecules and enzymes. According to a further aspect, the invention provides methods of detecting quorum sensing bacteria comprising use of such labelled ligands.

The invention also includes pharmaceutical compositions comprising LuxR, a homologue of LuxR, a fragment of LuxR, a fragment of a homologue of LuxR or a nucleic acid encoding one of these polypeptides, or a ligand capable of binding one of these polypeptides. The polypeptides, fragments thereof or nucleic acid encoding one of these polypeptides may induce

5   an immunogenic response in a host. Pharmaceutical compositions containing antibodies that immunoreact with LuxR or homologues of LuxR can be used to bind to bacteria, thus labelling them for attack by a host's·immune defences.

Vaccine compositions are also contemplated that comprise LuxR, a homologue of LuxR, a fragment of LuxR, a fragment of a homologue of LuxR or a nucleic acid encoding one of these

10   polypeptides or a quorum sensing signalling molecule. LuxR, a homologue of LuxR, a fragment of LuxR, a fragment of a homologue of LuxR or a nucleic acid encoding one of these polypeptides or a quorum sensing signalling molecule may be used to induce an immunogenic response in a host. Such responses will result in the production of antibodies and will prime the host's immune system against bacterial infection.

15   The invention also provides the use of LuxR, a homologue of LuxR, a fragment of LuxR or a homologue of LuxR, a nucleic acid encoding one of these polypeptides, a ligand, a pharmaceutical composition or a vaccine composition for use in therapy. Furthermore the invention provides the use of LuxR, a homologue of LuxR, a fragment of LuxR or a homologue of LuxR, a nucleic acid encoding one of these polypeptides, an antibody, a pharmaceutical

20   composition or a vaccine composition according to the invention in the manufacture of a medicament for the treatment of a disease in which quorum sensing is implicated. Such diseases include those caused by the bacteria *Bacillus subtilis, Streptococcus pneumoniae, Staphylococcus aureas, Vibrio salmonicida, Aeromonas hydrophila, Burkholderia stabilis, Burkholderia vietnamiensis, Burkholderia multivorans, Escherichia coli, Serratia marcescens,*

25   *Salmonella typhi, Brucella suis, Brucella melitensis, Yersinia ruckeri, Hafina alvei, shigella flexneri, Serratia liquefaciens, Enterococcus faecalis, Pseudomonas aeruginosa, Burkholderia cepacia, Pseudomonas fluorescens, Yersinia pestis, Yersinia enterocolitica* or *Yersinia pseudotuberculosis.*

The diseases include Crohn's disease and Cystic Fibrosis, cellulites and ecthyma, melioidosis,

30   meningitis, septicaemia, pneumonia, enteric infections and urinary tract infections, food poisoning, chest infections, typhoid fever, Malta disease, blood stream infections, shigellosis, salmonelliosis, black death and gastroenteritis, hitra disease in Atlantic salmon, haemmorrhagic

septicaemia in marine fish, spontaneous abortion in pigs and sheep, red mouth disease in rainbow trout, and cranial and eye lesions in fish.

The methods of the present invention may be used to inhibit bacteria. As used herein, inhibition of bacteria means the prevention of phenotypic change. Accordingly, the present invention provides a method of inhibiting bacteria comprising modulating the activation by a signalling molecule of LuxR or a homologue thereof.

The methods of the invention may also be used to inhibit biofilms. As used herein, inhibition of a biofilm includes prevention of biofilm formation and growth, and destruction of biofilms. Accordingly, the present invention provides a method of inhibiting a biofilm comprising modulating the activation by a signalling molecule of LuxR or a homologue thereof.

The invention also provides a method of detection of quorum sensing bacteria comprising;

(i) probing a sample of bacteria with a labelled ligand according to the invention, and

(ii) detecting the presence of ligand attached to bacteria.

In an alternative embodiment the method of detection of quorum sensing bacteria comprises;

(i) probing a sample of bacteria with a first ligand that binds to LuxR or a homologue of LuxR,

(ii) probing said first ligand with a second, labelled ligand, and

(iii) detecting the presence of the second antibody attached to bacteria.

Preferably the ligands used in the methods of detection are antibodies. More preferably they are monoclonal antibodies.

The invention also provides a method of detecting antibodies specific for LuxR or a homologue thereof comprising:

(i) probing a sample of serum with whole bacterial cells expressing whole or a fragment of LuxR or a homologue thereof,

(ii) probing the bacteria/antibody complex with a second, labelled antibody, and

(iii) detecting the presence of the second antibody attached to the bacteria/first antibody complex.

In an alternative embodiment, the method of detecting antibodies specific for LuxR or a homologue of LuxR comprises:

(i) probing a sample of serum with purified LuxR or a fragment or homologue thereof,

(ii) probing the bacterial protein/antibody complex with a second, labelled antibody, and

5   (iii) detecting the presence of the second antibody attached to the bacteria/first antibody complex.

Quorum sensing relies on signalling molecules to activate transcription. A variety of molecules are used as signalling molecules in quorum sensing as mentioned in Table 1. These ligands bind to their receptor which, for LuxR and its homologues, is found on the outer membrane of 10 bacteria. This then causes the initiation of transcription.

Ligands may be produced that immunoreact with LuxR, homologues of LuxR or fragments of these proteins. These ligands prevent the quorum sensing signalling molecules from binding to LuxR or its homologues, thus disrupting quorum sensing. This disruption can therefore prevent transcriptional activation and so prevent phenotypic changes associated with quorum sensing. 15 Examples of phenotypic changes that can be prevented include the production of luciferase mediated by LuxR and the production of virulence determinants mediated by LasR. Such downregulation of virulence determinant production by pathogenic bacteria thus provides an effective means of therapy. Accordingly the present invention provides a method of downregulating the production of virulence determinants comprising downregulating the 20 activation by a signalling molecule of a homologue of LuxR.

LasR is a homologue of LuxR and is a protein involved in virulence factor production in *Pseudomonas aeruginosa*. This organism has both cell-associated (flagella, pili and non-pilus adhesins, alginate/biofilm forming properties and lipopolysaccharide) and extracellular virulence factors (proteases, hemolysins, exotoxin A, exoenzyme S and pyocyanin). *Ps. aeruginosa* is a 25 cause of infection in Cystic Fibrosis, burns victims and those with immunodeficiencies. This makes it a desired target for therapy. Many strains are also resistant to a number of antibiotics.

Pseudomonas fluorescens has been shown to play a role in Crohn's disease. As well as causing infection in this disease state, it also encodes a T cell superantigen that results in autoimmunity, thus exacerbating disease (B. Wei *et al*. Infect Immun. 2002, 70(12):6567-75). It is known that 30 *Ps. fluorescens* has homologues of LuxR. It is therefore likely that these homologues of LuxR play a role in the production of virulence determinants important in Crohn's disease. Inhibition

of this signalling system is therefore likely to provide an effective method of therapy for the treatment of Crohn's disease by downregulating the production of said virulence determinants.

The methods of the invention may be applied to both Gram negative and Gram positive bacteria. Preferably the method of the invention is applied to Gram negative bacteria, preferably those

5 which utilise homoserine lactones (HSLs) as the signal molecule, and more preferably those that utilise N-acylated homoserine lactone as the signalling molecule. As detailed in Table 1, there are a wide variety of bacterial species that control their phenotypes by quorum sensing using a range of signalling molecules. Accordingly, the present invention provides a method of controlling a phenotype regulated by quorum sensing in bacteria comprising modulating the

10 activation by a signalling molecule of LuxR or a homologue thereof.

Table 1

Genus	Process(es) regulated	Signal Molecule(s)
Agrobacterium	Conjugation	HSLs
Enterococcus	Conjugation, pathogenesis	Peptides
Erwinia	Plant symbiosis	HSLs
Lactococcus	Bacteriocin production	Peptides
Myxococcus	Development	Peptides, amino acids
Pseudomonas	Mammalian pathogenesis	HSLs
Ralstonia	Plant pathogenesis	HSLs
Staphylococcus	Pathogenesis	Peptides
Streptococcus	Competence, virulence	Peptides
Streptomyces	Antibiotic production	γ-Butyrolactone
Vibrio	Bioluminescence	HSLs

Antibodies

LuxR, homologues of LuxR or fragments of these polypeptides can be used to generate ligands,

such as polyclonal or monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may be employed to isolate or to identify clones expressing these polypeptides or to purify the polypeptides by affinity chromatography. The antibodies may also be employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled

5   reader.

The term "immunospecific" means that the antibodies have greater affinity for the polypeptides used in the invention (namely LuxR, homologues of LuxR and fragments thereof) than for other polypeptides found on the bacterial membrane. As used herein, the term "antibody" refers to intact molecules, such as IgG, as well as to fragments thereof, such as Fab, F(ab')2 and Fv, which

10   are capable of binding to the antigenic determinant in question. Such antibodies thus bind to the polypeptides of the first aspect of the invention.

If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the method of the invention. The polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized

15   chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides may be chemically coupled include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography.

20   Monoclonal antibodies to the polypeptides used in the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C., Nature 256: 495-497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Cole et al., 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985).

25   Panels of monoclonal antibodies produced against the LuxR and homologous polypeptides can be screened for various properties, i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding the monoclonal antibodies of interest may be isolated from hybridomas, for instance by PCR techniques known in the art, and cloned and expressed in

30   appropriate vectors.

Chimeric antibodies, in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu et al., Proc. Natl. Acad. Sci. USA, 84, 3439 (1987)), may also be

of use.

The antibody may be modified to make it less immunogenic in an individual, for example by humanisation (see Jones *et al.*, Nature, 321, 522 (1986); Verhoeyen *et al.*, Science, 239, 1534 (1988); Kabat *et al.*, J. Immunol., 147, 1709 (1991); Queen *et al.*, Proc. Natl. Acad. Sci. USA, 86, 10029 (1989); Gorman *et al.*, Proc. Natl Acad. Sci. USA, 88, 34181 (1991); and Hodgson *et al.*, Bio/Technology, 9, 421 (1991)). The term "humanised antibody", as used herein, refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody. The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody.

In a preferred example, fragments of LuxR or homologues of LuxR may be chosen and used as the antigen against which antibodies are raised. Obviously there are areas of high sequence identity between these homologues and to avoid the likelihood of cross-reactivity of antibodies, areas of low homology should be used as the antigen. This allows the production of antibodies that are specific to a particular organism and therefore treatments involving the use of such antibodies would not affect desired commensal organisms. In the present invention it has been discovered that the region between amino acids 19 and 31 is of low homology and this has been chosen for use in raising antibodies that are immunospecific for LuxR.

Anti-idiotypic antibodies may be raised, using methods known in the art, against the antibodies of the invention that immunoreact with LasR. These may bind to signalling molecules and sequester these molecules, thus preventing them from binding and activating LuxR or a homologue of LuxR.

Detection tests

Antibodies generated by the above techniques, whether polyclonal or monoclonal, have additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA) for the detection of bacteria utilising quorum sensing or signalling molecules. In these applications, the antibodies can be labelled with an analytically-detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme.

Antibodies which specifically bind to the LuxR protein, homologues and fragments thereof may be used for the diagnosis of conditions or diseases characterised by expression of the

polypeptide, or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, ligands and other compounds. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect the polypeptide in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules known in the art may be used, several of which are described above. The invention also provides a diagnostic assay in kit form.

The signal molecule involved in quorum sensing, which in many cases is AHL, may be conjugated with a label such as a radioisotope, a fluorescent molecule or an enzyme. This may then be used in assays to detect the presence of cells that use quorum sensing.

A further type of detection test involves the screening for antibodies that are specific for LuxR or homologues thereof, and thus indicate disease. One way of doing this would be to use anti-idiotypic antibodies as mentioned above to probe for antibodies specific for LuxR or homologues thereof.

Bacteria expressing homologues of LuxR may be used to detect the presence of antibodies immunoreactive with those homologues in serum samples. Binding of antibodies to the bacteria could be detected using suitable labelled secondary antibodies.

Pharmaceutical Compositions

The invention also provides pharmaceutical compositions comprising LuxR, a homologue of LuxR, a nucleic acid encoding one of these polypeptides, fragments of these polypeptides or a ligand that binds one of these polypeptides in combination with a suitable pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below.

The pharmaceutical compositions should preferably comprise a therapeutically effective amount of LuxR, a homologue of LuxR, a fragment thereof, a nucleic acid encoding one of these polypeptides or a ligand that binds one of these polypeptides. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate, or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration

range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.

A pharmaceutical composition may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

The pharmaceutical compositions utilised in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for

example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal means. Gene guns or hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions; solid

5   forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a

10 single dose schedule or a multiple dose schedule.

If the activity of the polypeptide of the invention is in excess in a particular disease state, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as described above, along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of

15 ligands, substrates, enzymes, receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously.

20 Gene Therapy

Gene therapy may be used to insert a nucleic acid encoding LuxR, a homologue of LuxR or a signalling molecule. This would result in production of one of these proteins which could then elicit an immune response. Such an immune response could be used to protect a host against bacterial infection. Gene therapy utilising a nucleic acid encoding LuxR, a homologue of LuxR

25 or a fragment of those polypeptides, can occur *in vivo* or *ex vivo*. *Ex vivo* gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. In contrast, *in vivo* gene therapy does not require isolation and purification of a patient's cells.

The therapeutic gene is typically "packaged" for administration to a patient. Gene delivery

30 vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K.L., in Curr. Top. Microbiol. Immunol., 158, 39-66 (1992) or adeno-

associated virus (AAV) vectors as described by Muzyczka, N., in Curr. Top. Microbiol. Immunol., 158, 97-129 (1992) and U.S. Patent No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of the invention may be engineered for expression in a replication-defective retroviral vector. This expression construct may then be isolated and

5   introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding the polypeptide, such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo* (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited

10   therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd).

Another approach is the administration of "naked DNA" in which the therapeutic gene is directly injected into the bloodstream or muscle tissue.

Vaccines

15   Vaccines according to the invention may be prophylactic (*i.e.* to prevent infection) or therapeutic (*i.e.* to treat disease after infection). Such vaccines comprise polypeptide(s) or protein(s) according to the first aspect of the invention or nucleic acid according to the second aspect of the invention, usually in combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies harmful to the

20   individual receiving the composition. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, and other pathogens.

Since polypeptides may be broken down in the stomach, vaccines comprising polypeptides are

25   preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.

30   The vaccine formulations of the invention may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The dosage will

depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Genetic delivery of antibodies that bind to polypeptides according to the invention may also be effected, for example, as described in International patent application WO98/55607.

5   The technology referred to as jet injection (see, for example, www.powderject.com) may also be useful in the formulation of vaccine compositions.

A number of suitable methods for vaccination and vaccine delivery systems are described in International patent application WO00/29428.

10 ·   **BRIEF DESCRIPTION OF DRAWINGS**

Figure 1 shows an alignment of LuxR homologues. Sequences aligned using the Clustal alignment algorithm included in the LaserGene sequence analysis package. Black = invariant residues. From: Stevens, AM & Greenberg, EP (1999) Transcriptional Activation by LuxR. In: Cell-Cell Signalling in Bacteria, Eds. Dunny, GM & Winans, SC, American Society for

15   Microbiology p238.

Figure 2 shows FITC labelled *V. fischeri* cells after pre-incubation with anti-LuxR, in A. pre-glowing; B. glowing; and C. post-glowing phases of growth.

Figure 3 shows FITC labelled *Ps. aeruginosa* cells after pre-incubation with anti-LasR.

Figure 4 shows electron microscopy images demonstrating the morphology of *V. fischeri* cells in

20   pre-quorate (pre-glowing), quorate (glowing) and post-quorate (post-glowing) phases of growth.

Figure 5 shows an AFM image demonstrating bipolar location of LuxR in *V. fischeri* cells

Figure 6 shows an autoradiograph from immunoprecipitated *V. fischeri* cell membranes. Key to lanes: 1 & 10 – Markers; 2 & 9 – Empty; 3 – Anti-luciferase antisera (X 10 dilution); 4 – Anti-luciferase antisera (undiluted); 5 – Commercial anti-LuxRp antisera (X10 dilution); 6 –

25   Commercial anti-LuxRp antisera (undiluted); 7 – Peptide anti-LuxRp antisera (X10 dilution); 8 – Peptide anti-LuxRp antisera (undiluted).

Figure 7 shows the changes in optical density and bioluminescence for *V. fischeri* cells with and without pre-incubation with commercial anti-LuxR antisera.

Figure 8 shows changes in bioluminescence for *V. fischeri* cells with and without pre-incubation with the in-house prepared anti-LuxR antisera.

MODES FOR CARRYING OUT THE INVENTION

5   LuxR has been previously described as being found on the inner leaflet of the bacterial cyoplasmic membrane. It is now postulated that it is only found here during certain phases of growth. Furthermore, the present invention shows that LuxR it is found on the outer surface of the outer membrane in pre-quorate and quorate cells. The signalling molecule (in the case of LuxR, N-acylated homoserine lactone) is able to bind to the receptor LuxR. It is believed that

10   once the signalling molecule has bound, the complex is internalised and transcription is initiated.

As figure 1 shows, there are a number of homologues of LuxR. It is predicted that, during the pre-quorate and quorate phases, these homologues are also found on the outer surface of the outer membrane. As Table 2 shows, a number of bacterial species use N-acylated homoserine lactones as a quorum sensing signalling molecule.

15

Table 2: Bacteria that produce N-acylated homoserine lactones

Agrobacterium spp.
Rhizobium spp.
20   *Rhodobacter sphaeroides*
Burkholderia cepacia
Chromobacterium violaceum
Nitrosomonas europaea
Ralstonia solanacearum
25   *Aeromonas* spp.
Citrobacter spp.
Enterobacter spp.
Erwinia spp.
Hafnia spp.
30   *Obesumbacterium* spp.
Pseudomonas aeruginosa
Pseudomonas aureofaciens
Pseudomonas fluorescens
Pseudomonas syringae
35   *Pseudomonas putida*
Rahnella aquatilis
Serratia spp.

Proteus spp.
Vibrio fischeri
Vibrio anguillarum
Vibrio harveyi
5   *Vibrio fluvialis*
Vibrio logei
Vibrio metschnikovii
Xenorhabdus nematophilus
Yersinia spp.
10

Example 1: Identification of the location of LuxR and its homologues by FITC Labelling

Vibrio fischeri NRRL B-11177 (ATCC 7744) cells were grown at 25°C in 50ml volume nutrient broth (Oxoid) +2% NaCl in 250ml flasks in an orbital shaker set at 200rpm. *Pseudomonas aeruginosa* NCIMB 10548 was used in the experiments.

15   A commercially available polyclonal anti-luxR was obtained from Quorum Sciences Inc., Iowa. Polyclonal anti-lasR was kindly provided by Dr. Steven Diggle, University of Nottingham.

1ml samples of cells at the appropriate stage of the cell cycle (pre-quorate, quorate and post quorate) were aliquoted into 1.5ml capacity microfuge tubes and centrifuged at 10,000 rpm for 3 minutes. Supernatants were discarded and the cell pellets re-suspended in 1ml of 1 x PBS. Cells

20   were then washed twice more in 1ml 1x PBS before final re-suspension in 500µl 1xPBS. 25µl of the appropriate antibody (1:1000 dilution) was then added to samples and cells incubated at 25°C for 1 hour. Cells were washed three times in 1x PBS and then re-suspended in a final volume of 500µl 1x PBS.

25µl of an anti-rabbit FITC labeled secondary antibody (1:1000 dilution) was then added to test

25   samples and cells were incubated at 25°C for a further 1 hour. Finally, cells were washed three times in 1x PBS to remove all unbound antibody and re-suspended in a 500µl volume of 1x PBS. Control samples were set up without antibody addition and also with the addition of the secondary antibody or primary antibody only.

For microscopic observation, a small drop of the test sample was mixed with an equal volume of

30   mowiol, a setting agent, on a plain glass slide. A coverslip was placed over the sample and allowed to stand at 4°C for 20 minutes to allow the setting agent to take effect. Slides were visualised using a Leica TCS 4D confocal microscope with appropriate FITC fluorescence filters.

Figures 2 and 3 demonstrate that LuxR and LasR are found on the outer surface of the cell

35   cytoplasmic membrane, as anti-LuxR and anti-LasR respectively are able to bind to the bacteria.

The FITC labelled cells are shown as glowing spots against the dark background. In figure 2, there appear to be more labelled cells before the population is quorate (pre-glowing). It is postulated that LuxR and its homologues are only present on the cell membrane before quorum is reached. As quorum is reached, signalling molecules bind to LuxR and its homologues and the resultant complexes are internalised. Therefore there are few molecules of LuxR on the membrane of quorate cells, so antibody cannot bind.

Example 2: Identification of the location of LuxR and its homologues by Gold-labelling and Electron microscopy

Preparation of Morphological Fixative

An 8% (v/v) stock solution of paraformaldehyde was prepared by dilution in distilled water with stirring at 60°C. 1M NaOH was added drop-wise until the solution became clear.

A 25% stock solution of glutaldehyde was prepared by dilution in distilled water. This 25% solution was then diluted 1/10 in 2x PBS to make a 2.5% solution.

The immunological fixative was prepared by combining 40ml paraformaldehyde, 4ml glutaldehyde, 50ml 2 x PBS and 6 ml distilled water.

Preparation of Cells

The centrifuged pellet from 1ml of *V. fischeri* cell sample was placed into 2ml of immunological fixative, re-suspended and left at room temperature for at least 2 hours.

Following fixing, the cells were washed three times in 1x PBS before re-suspension in 1ml of 30% IMS for 1 hour at 4°C.

Cells were then centrifuged at full speed for 1 minute and re-suspended in a fresh solution of 60% IMS. The samples were then left for 1 hour at 4°C. The process was then repeated with a 90% IMS solution followed by two changes of 100% and incubated overnight in 100% IMS at -20°C.

Cells then underwent two more changes of 100% IMS, each time being left for 1 hour at -20°C. Cell samples were then centrifuged again and the IMS replaced with 1ml of 100% de-watered ethanol and 1ml lowiacryl resin. Samples were then placed in a freezer at -35°C for 1 hour.

The lowiacryl/ethanol mix was then replaced with 100% lowiacryl which was then changed three times over a two-day period with samples kept at a constant temperature of -35°C.

Samples were then centrifuged at full speed for 5 minutes and pellets transferred to the bottom of gelatine capsules before being topped up with lowiacryl to eliminate most of the oxygen, which can interfere with the polymerisation, and capped.

Samples were then left at -35°C, partially covered with tin foil to prevent cracking of the samples, which can occur with direct exposure to the UV lamp required for polymerisation.

Finally the samples were placed at 25°C under the UV lamp for a further 12 hours to complete the polymerisation process.

Samples were then cut using a diamond knife on a microtome and the sections floated onto nickel grids and dried.

Antibody Binding

The nickel grids onto which cell samples had been placed were then floated in a 50µl droplet of anti-luxR for 1 hour at 20°C. This was followed by three washes in 1x PBS before floating in 50µl of a gold-labeled protein A antibody for a further hour.

Grids were then washed three times in 1x PBS before being stained with uranyl acetate at 60°C for 10 minutes, dried and examined using a Philips TEM electron microscope at magnifications of between x9100 and x40,000.

Atomic Force Microscopy

Preparation of Cells

1ml cell samples were centrifuged at 10,000rpm for 3 minutes and the pellet then re-suspended in 500µl 1x PBS. Cells were then incubated with 25µl of anti-luxR for 1 hour at room temperature. Samples were then washed three times in 500µl of 1x PBS before the addition of 25µl of protein A labeled with 10nm diameter gold particles. Cells were again incubated for 1 hour at room temperature in the presence of the protein A and then washed three times in 1x PBS.

Preparation of fixed cell samples

In order to visualize the cells a small drop of the appropriate sample was placed in the middle of a 1cm diameter glass coverslip which had been previously glued to a 1cm steel disc for which the AFM has a magnetic receptor. The drop of sample was left to settle for 1 hour and then any remaining liquid was blotted off with tissue. Discs were then studied using the AFM.

AFM Parameters

The atomic force microscope was used in the "tapping mode" which allowed us to get very high-resolution images of the surface of individual cells with minimal risk of damage to the cell sample. The tapping probe was set up with a 20μm sweep such that a sizeable section of the sample could be overviewed initially. When a cell of particular interest was seen the sweep was

5   reduced to 5μm over the area of interest to give better resolution.

Figure 4 shows the change in morphology of *V. fischeri* cells at the following stages of the cell cycle, pre-glowing (pre-quorate), glowing (quorate) and post-glowing (post-quorate). Figure 5 is an AFM picture showing the polar binding of anti-LuxR. Clusters of the bound gold-conjugated antibody can be seen at the two poles of the bacteria. Figure 4 also shows the reaction with

10 antisera.

Example 3: Identification of the location of LuxR and its homologues by immunoprecipitation

Cultures of *V. fischeri* were grown in nutrient broth with 2% NaCl added. 200nM AHL was

15 included in the medium, prepared as 100ml volume in 250ml flasks.

Cultures were grown at 26°C and 20ml aliquots taken at the pre-quorate (OD < 0.15 at 595nm), quorate (OD < 0.4 at 595nm) and post-quorate (OD > 0.5nm at 595nm) stages. Cells were labelled for 1 hour with 10μCi [^{35}S] methionine ml^{-1}.

Labelled cells were then harvested by centrifugation at 3500rpm for 5 mins at room temp.

20 [^{35}S] methionine labelled cells were re-suspended in 4ml of 10mM Tris buffer (pH 7.5 at 4°C) containing 1mM MgCl$_2$ and 1μg DNAse I per ml. Lysozyme (50mg/ml in 0.1M EDTA, pH 8) was added to a final conc of 50μg ml^{-1}.

Cells were incubated on ice for 30 minutes and then broken by sonication on ice at 14μm for 90 seconds. Remaining whole cells were removed by centrifugation at 1000rpm for 2 minutes at

25 4°C. The membranes and soluble components were separated by ultracentrifugation at 100,000 x g for 45 minutes at 4°C. Membranes were then suspended in 1ml of cold 25% sucrose (w/w) ready for density gradient centrifugation.

For sucrose density gradient centrifugation, step gradients were prepared by layering 2.1ml each of 50, 45, 40, 35, and 30% sucrose. 1ml of membrane suspension (containing up to 8mg of

30 protein) was layered on top of the gradient and centrifugation carried out at 35,000rpm for 16 hours at 4°C. 1ml fractions were then drawn off into eppendorf tubes and fractions of interest

were found by taking 100µl samples of each and mixing with 3ml of Optiphase "Hi-Safe–3"™ scintillation fluid (Wallac/Perkin Elmer). Disintegrations per minute (DPM) were recorded over a 60 second period using a Wallac 1410 liquid scintillation counter and those fractions showing significantly high DPM values were selected for immunoprecipitation treatment.

5   Samples for immunoprecipitation were treated with 1% SDS in a boiling heating block for 2 minutes followed by 50% dilution in triton buffer (0.1% triton-100 in ddH$_2$O pH 7.0). Non-specific precipitates were then removed by centrifugation at 6000rpm for 3 minutes. Supernatants were then mixed with 20µl of a 1:1000 dilution of antiserum (anti-luxR 1, anti-luxR 2, or anti-luciferase). To this mixture was added 500µg ml^{-1} of Staphylococcus protein A.

10   The tubes were then incubated on ice for 20 minutes to allow formation of antibody-protein-A complexes. The complexes were then pelleted out via centrifugation for 2 minutes at 13 000rpm and 4°C.

Complexes were washed twice in 50mM Tris buffer (pH 8) before being boiled for 5 minutes in 100µl of a 1% SDS sample buffer. Proteins in the supernatants were then separated using
15   standard SDS gel electrophoresis techniques. Gels were stained by immersing in Coomassie blue overnight, followed by destaining until bands were resolved. Gels were then washed thoroughly by immersing in ddH$_2$O for 1 hour then ddH$_2$O + 3% glycerol to prevent cracking of the gel on drying. Gels were then dried at 75°C for 2 hours using a Biorad 543 gel dryer set on the slow increase temperature ramp cycle to minimise curling of the gel.

20   Gels were exposed to Amersham Pharmacia Hyperfilm™ MP autoradiography film. The film was pre-flashed under darkroom conditions using an Amersham "Sensitize™" flash gun which was held 75cm from the film and gave an optical density of 0.15 at 545nm upon test processing samples (the ideal being 0.1-0.2 at 545nm). This process hypersensitised the film prior to exposure to the radio-labelled gels. Gels were then placed into a film cassette and overlaid with
25   the pre-flashed film. The cassette was sealed to ensure total evacuation of light and then placed at -80°C for 10 days. Film was then developed using a Kodak XP-4 film processor.

The results of the immunoprecipitation are shown in the autoradiographs in Figure 6. In 6A, lanes 5, 6 and 7, where anti-LuxR antisera was used as a probe, clearly show bands, indicating that LuxR was present in the membrane. In 6B, the bands are less distinct, indicating a lower
30   number of LuxR molecules in the membrane. The lack of bands in 6C shows that post-quorate cells do not have detectable amounts of LuxR in the membrane.

Example 4: Production of polyclonal antibody

Production of Synthetic Peptide

A short synthetic peptide was produced on site in the Protein Science Facility according to the methods of Fields *et al.* (1990). The peptide sequence was chosen from a region close to the N-
5   terminus of the luxR protein of *V.fischeri* strain ES114 (ATCC 700601). The sequence is shown below.

N-terminal residue   T C N N N K D I N Q C   C-terminal residue

The chosen sequence was located between amino acids 20-30 inclusive from the N-terminus of luxR to avoid the region of the protein responsible for negative autoregulation.

10   Activated Keyhole Lymphocyte Haemocytoma (KLH) Preparation

0.5ml (30mg) of KLH (Cal Biochem) was dialysed overnight in 1 litre 50mM Phosphate buffer, pH 7.5, 4°C. 8mg of m-Maleimidobenzoyl-*N*-hydroxysuccinamide ester (MBS) dissolved in dry dimethyformamide (DMF) was added dropwise to the stirred KLH solution at room temperature and a precipitate was seen to form. The reaction mix was stirred in a stoppered vial for 30
15   minutes then 100µl glycyl glycine (50mg/ml in phosphate adjusted to pH7 with 1M NaOH) was added. The solution was the centrifuged at 13,000rpm for 10 minutes resulting in a clear greyish solution.

The solution of activated KLH was then desalted over a Pharmacia fast desalting column equilibrated and eluted with 50mM phosphate buffer pH7.5. The protein concentration was then
20   determined using a standard Bradford assay and stored as 3-4mg aliquots at -80°C.

The synthetic peptide was then coupled to KLH using the procedure according to McCray *et al.* (1989). 3 mg of peptide were dissolved in 100µl 50mM phosphate buffer and the pH adjusted to 7.0 using 400mM phosphate buffer pH 7.4. Half of the peptide solution was mixed with an aliquot of activated KLH and stirred in the dark for 3 hours. This mix was then dialysed into 1
25   litre of 1x PBS overnight. The solution was the centrifuged at 13,000rpm for 10 minutes and desalted on a Pharmacia rapid desalting column equilibrated and eluted with 1x PBS. The protein concentration was determined using a standard Bradford assay and aliquoted as 400µg aliquots, the equivalent of 1 rabbit immunogen dose.

Immunisation of the Rabbit

For the primary immunisation, 400µg of the KLH/peptide conjugate was combined with a small volume (~100µl) of Freunds Complete Adjuvant (FCA) and administered. Two further boosters were administered at two weekly intervals. A test bleed was taken after the third injection and

5 purified using an affinity purification technique. Dependant on the titre of antibody at that stage a further two boosters could be administered prior to the terminal bleed.

Purification

3mg of the luxR peptide was dissolved in 2ml of coupling buffer (50mM Tris-HCl pH 8.5 containing 5mM EDTA). 3ml of "Sulfolink" coupling gel (Pierce) were transferred to a Biorad

10 Econo-column® and washed with 12ml of coupling buffer. The peptide solution was applied to the column and then the column stoppered and mixed end over end at room temperature for 15 minutes. The column was then allowed to stand at room temperature for 30 minutes. The column was then drained and washed with 15ml of coupling buffer. 1.5ml of blocking agent (30µl β-mercaptoethanol in 5ml coupling buffer) was added to the column and then mixed end over end

15 for 15 minutes followed by standing for 30 minutes at room temperature. Finally the column was drained and washed with 15ml 1M NaCl followed by 15 PBS +0.02% sodium azide.

2µl 5mg/ml leupeptin, 2µl 1mg/ml pepstatin in EtOH and 2µl 100mM PMSF in isopropanol were added to 4ml of serum to inhibit proteolysis.

The serum was then applied to an appropriate affinity column equilibrated with PBS at a rate of

20 15ml/hr. The flowthrough was collected for assay of possible unbound antibody. The flow rate was then increased to 30ml/hr and washed with 10 column volumes of PBS followed by 10 column volumes of PBS containing 1M NaCl.

The antibody was then eluted with 0.1M glycine pH 2.8, containing 0.15M NaCl collecting 15x 2ml fractions. The acidic fractions were neutralised as soon as possible with 2M Tris, testing 2µl

25 aliquots on pH paper.

The column was also quickly neutralised with 0.1M sodium phosphate pH 7.4 and then washed with PBS containing 0.02% sodium azide for storage.

A dot blot was then carried out using a 3'3-Diaminobenzidine (DAB) stain to locate relevant fractions by probing with a peroxidase conjugated secondary antibody.

For storage the antibody containing fractions were made 1% with respect to bovine serum albumin and dialysed overnight against PBS. After dialysis 0.02% sodium azide was added and then the antibody stored as 500µl aliquots at -20°C.

5   **Example 5: Monitoring light output of cells using luminometry**

1ml aliquots of the culture samples, grown in luminescence media consisting of 5% yeast extract, 5% tryptone peptone, 1% $CaCO_3$ and 3% glycerol in filtered seawater, were placed into cylindrical, flat-bottomed cuvettes. No washing of the cells was required and light output was measured using a BioOrbit 1253 luminometer connected to a computer running the Lumicom™

10   data processing software. Light output was measured on a linear arbitrary scale, assuming zero to be complete darkness. Each reading was performed in triplicate and averaged.

For phenotype blocking using the commercial or in-house prepared polyclonal anti-LuxR, 1ml samples of pre-quorate (Abs. ~ 0.2 at 595nm) *V. fischeri* cells were inoculated into 50ml volume of sterile NB + 2% NaCl. 25µl of a 1:100 dilution of the appropriate antibody was then added to

15   flasks. Cultures were incubated at 25°C with shaking for 1 hour before the addition of 25µl of a 5mg/ml solution of synthetic AHL (2.5µg ml^{-1}). Absorbance (595nm) and light output of cultures recorded immediately following AHL addition and at hourly intervals thereafter.

20   It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

CLAIMS

1. A method of regulating quorum sensing in bacteria comprising modulating the activation by a signalling molecule of LuxR or a homologue thereof.

2. A method according to claim 1 wherein activation of LuxR or a homologue of LuxR by a signalling molecule is prevented.

3. A method according to claim 1 or claim 2 wherein said bacteria are Gram negative.

4. A method according any of claims 1 to 3 wherein said homologue of LuxR is selected from the list consisting of AhyR, AsaR, BviR, CarR, CepR, CerR, CinR, CsaR, CviR, EchR, EsaR, ExpR, HalR, LasR, LuxS, Mll8752, MupR, PhzR, PpuR, PsmR, PsyR, RaiR, RhiR, RhlR, SdiA, SdiR, SmaR, SolR, SpnR, SprR, SwrR, TraR, TrnR, VanR, YenR, YpeR, YpsR, YruR, YtbR and YukR.

5. A method according to any of claims 1 to 4 wherein the signalling molecule is a N-acylated homoserine lactone.

6. A method according to any one of claims 1 to 5 wherein the binding of a ligand prevents the LuxR or homologue of LuxR from being activated by its signalling molecule.

7. A method according to claim 6 wherein said ligand is an antibody.

8. A method according to claim 7 wherein said antibody is a monoclonal antibody.

9. An antibody that immunoreacts with LuxR or a homologue of LuxR between amino acid residues 19 and 80.

10. An antibody according to claim 9 wherein said antibody immunoreacts with LuxR or a homologue of LuxR between amino acid residues 19 and 31.

11. An antibody according to claim 9 or claim 10 which immunoreacts with the sequence TCNNNKDINQC.

12. An anti-idiotypic antibody that binds to an antibody according to any one of claims 9 to 11.

13. An antibody according to any of claims 9 to 12 conjugated to a detectable label.

14. An antibody according to claim 13 wherein said label is a radioisotope, a fluorescent molecule, a heavy metal molecule or an enzyme.

15. A pharmaceutical composition comprising LuxR, a homologue of LuxR, a fragment of LuxR, a fragment of a homologue of LuxR or a nucleic acid encoding one of these polypeptides, or an antibody according to any one of claims 9 to 14.

16. A vaccine composition comprising LuxR, a homologue of LuxR, a fragment of LuxR, a fragment of a homologue of LuxR, a nucleic acid encoding one of these molecules or a quorum sensing signalling molecule.

17. A vaccine composition according to claim 16 wherein said quorum sensing signalling molecule is a N-acylated homoserine lactone.

18. A vaccine composition according to claim 16 or claim 17 further comprising a pharmaceutically acceptable diluent or carrier.

19. A vaccine composition according to any one of claims 16 to 18, further comprising an adjuvant.

20. LuxR, a homologue of LuxR, a fragment of LuxR or a homologue of LuxR, a nucleic acid encoding one of these polypeptides, an antibody according to any one of claims 9 to 14, a pharmaceutical composition according to claim 15, or a vaccine composition according to claims 16 to 19 for use as a medicament.

21. Use of LuxR, a homologue of LuxR, a fragment of LuxR or a homologue of LuxR, a nucleic acid encoding one of these polypeptides, an antibody according to any one of claims 9 to 14, a pharmaceutical composition according to claim 15, or a vaccine composition according to claims 16 to 19 in the manufacture of a medicament for the treatment of disease in which quorum sensing is implicated.

22. The use of claim 21 wherein disease is caused by *Bacillus subtilis, Streptococcus pneumoniae, Staphylococcus aureas, Vibrio salmonicida, Aeromonas hydrophila, Burkholderia stabilis, Burkholderia vietnamiensis, Burkholderia multivorans, Escherichia coli, Serratia marcescens, Salmonella typhi, Brucella suis, Brucella melitensis, Yersinia ruckeri, Hafina alvei, shigella flexneri, Serratia liquefaciens, Enterococcus faecalis, Pseudomonas aeruginosa, Burkholderia cepacia, Pseudomonas fluorescens, Yersinia pestis, Yersinia enterocolitica* or *Yersinia pseudotuberculosis*.

23. The use according to claim 21 or claim 22 wherein said disease is Crohn's disease or Cystic Fibrosis, cellulites and ecthyma, melioidosis, meningitis, septicaemia, pneumonia, enteric infections and urinary tract infections, food poisoning, chest infections, typhoid

fever, Malta disease, blood stream infections, shigellosis, salmonelliosis, black death and gastroenteritis, hitra disease in Atlantic salmon, haemmorrhagic septicaemia in marine fish, spontaneous abortion in pigs and sheep, red mouth disease in rainbow trout, and cranial and eye lesions in fish.

24. Use of a method according to any one of claims 1 to 8 for the inhibition of biofilms.

25. A method of detection of quorum sensing bacteria comprising;

   (i) probing a sample of bacteria with a labelled antibody according to claim 13 or claim 14, and

   (ii) detecting the presence of antibody attached to bacteria.

26. A method of detection of quorum sensing bacteria comprising;

   (i) probing a sample of bacteria with a first antibody according to any one of claims 7 to 10,

   (ii) probing said first antibody with a second, labelled antibody, and

   (iii) detecting the presence of the second antibody attached to bacteria.

27. A method of detecting antibodies specific for LuxR or a homologue thereof comprising:

   (i) probing a sample of serum with whole bacterial cells expressing whole or a fragment of LuxR or a homologue thereof,

   (ii) probing the bacteria/antibody complex with a second, labelled antibody, and

   (iii) detecting the presence of the second antibody attached to the bacteria/first antibody complex.

28. A method of detecting antibodies specific for LuxR or a homologue thereof comprising:

   (i) probing a sample of serum with purified LuxR or a fragment or homologue thereof,

   (ii) probing the bacterial protein/antibody complex with a second, labelled antibody, and

   (iii) detecting the presence of the second antibody attached to the bacteria/first antibody complex.

29. A kit comprising an antibody according to any one of claims 8 to 14.

30. A kit comprising a fragment of LuxR or a fragment of a homologue of LuxR for the detection of antibodies thereto.

31. A method of inhibiting quorum sensing comprising sequestering quorum sensing signal molecules.

32. Use of an antibody according to claim 12 in the method of claim 29.

ABSTRACT

The invention relates to a method of regulating quorum sensing in bacteria by modulating the activation of LuxR or a homologue thereof. Such modulation generally occurs when the bacteria are in the pre-quorate or quorate stage and may be achieved by targeting antibodies to

5   LuxR or a homologue thereof.

AsaR
RhlR
PhzR
LuxR
EsaR
ExpR
YenR
TraR
TrpR
VanR
LasR
CerR
RhiR
RaiR
SdiA

Figure 1

Figure 2: FITC labelled *V. fischeri* cells after pre-incubation with anti-LuxR

A. Pre-glowing

B. Glowing

C. Post-glowing

Figure 3: FITC labelled *Ps. aeruginosa* after pre-incubation with anti Las-R

Figure 4: Electron microscope images showing the morphology of *V. fischeri* in different stages of the cell cycle.

Pre Glowing

Glowing

Post Glowing

Figure 5: AFM image showing the bipolar location of LuxR in *V. fischeri* cells.

Figure 6: Autoradiograph from immunoprecipitated *V. fischeri* membranes

A. Pre-glowing cells.

B. Glowing cells.

C. Post-glowing cells.

Figure 7: Changes in bioluminescence for *V. fischeri* cells with and without pre-incubation with commercial anti-LuxR antisera.

Figure 8: Changes in bioluminescence for *V. fischeri* cells with and without pre-incubation with the in-house prepared anti-LuxR antisera.

PCT/GB2004/004775